LB0001 Long-Term (52-Week) Results of a Phase 3, Randomized, Controlled Trial of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis

Arthur Kavanaugh, Philip J. Mease, Ade Adebajo, J. Wollenhaupt, C. Hu, K. Shah, R. Stevens, Juan J. Gómez‐Reino

Annals of the Rheumatic Diseases · 2013 · 46 citations · 0 references

Concepts